Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185)
Hong Kong · Delayed Price · Currency is HKD 4.410
+0.070 (1.61%)
May 7, 2026, 3:57 PM HKT
HKG:2185 Revenue
In the year 2025, Shanghai Bio-heart Biological Technology had annual revenue of 44.93M CNY. Shanghai Bio-heart Biological Technology had revenue of 24.07M in the half year ending December 31, 2025.
Revenue
44.93M CNY
Revenue Growth
n/a
P/S Ratio
21.47
Revenue / Employee
691.26K CNY
Employees
65
Market Cap
1.07B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 44.93M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 3D Medicines | 396.26M |
| Cutia Therapeutics | 374.07M |
| JW (Cayman) Therapeutics Co. | 315.65M |
| Wuhan YZY Biopharma | 74.40M |
| CANbridge Pharmaceuticals | 55.62M |
| Brii Biosciences | 39.56M |
| Beijing Biostar Pharmaceuticals | 37.13M |
| Kintor Pharmaceutical | 36.37M |